Results for tag: "Metachromatic Leukodystrophy Drug"

Metachromatic Leukodystrophy (MLD) is a rare, inherited, genetic disorder that affects the central nervous system. It is caused by a deficiency of the enzyme arylsulfatase A (ASA). MLD is characterized by progressive neurological deterioration, including cognitive and motor deficits, and can lead to death. Treatment for MLD is limited to supportive care and enzyme replacement therapy (ERT). ERT is the only approved treatment for MLD and is used to replace the missing enzyme in the body. The MLD drug market is a small but growing segment of the Central Nervous System (CNS) drugs market. It is driven by the increasing prevalence of MLD, the development of new treatments, and the increasing awareness of the disease. The market is expected to grow at a moderate rate over the forecast period. Companies in the MLD drug market include Shire, Sanofi, Genzyme, and Biomarin. These companies are involved in the development and commercialization of ERT drugs for the treatment of MLD. Show Less Read more